A5027458313- SARS-CoV-2 and COVID-19 Research
- SARS-CoV-2 detection and testing
- COVID-19 Clinical Research Studies
- Animal Virus Infections Studies
- CRISPR and Genetic Engineering
- Bacteriophages and microbial interactions
- Viral Infections and Vectors
- Computational Drug Discovery Methods
- Viral Infections and Outbreaks Research
- vaccines and immunoinformatics approaches
- Plant Virus Research Studies
- Mosquito-borne diseases and control
- Vaccine Coverage and Hesitancy
- Viral gastroenteritis research and epidemiology
- Monoclonal and Polyclonal Antibodies Research
Copenhagen University Hospital
2022-2024
University of Copenhagen
2022-2024
Hvidovre Hospital
2023
The oral protease inhibitor nirmatrelvir is of key importance for prevention severe coronavirus disease 2019 (COVID-19). To facilitate resistance monitoring, we studied acute respiratory syndrome 2 (SARS-CoV-2) escape from in cell culture. Resistant variants harbored combinations substitutions the SARS-CoV-2 main (Mpro). Reverse genetics revealed that E166V and L50F + conferred high infectious culture, replicon, Mpro systems. While L50F, E166V, decreased replication activity, had fitness...
Abstract The oral protease inhibitor nirmatrelvir is expected to play a pivotal role for prevention of severe cases coronavirus disease 2019 (COVID-19). To facilitate monitoring potentially emerging resistance, we studied acute respiratory syndrome 2 (SARS-CoV-2) escape from nirmatrelvir. Resistant variants selected in cell culture harbored different combinations substitutions the SARS-CoV-2 main (Mpro). Reverse genetic studies homologous infectious system revealed up 80-fold resistance...
Capsid virus-like particles (cVLP) have proven safe and immunogenic can be a versatile platform to counter pandemics. We aimed clinically test modular cVLP COVID-19 vaccine in individuals who were naive SARS-CoV-2.In this phase 1, single-centre, dose-escalation, adjuvant-selection, open-label clinical trial, we recruited participants at the Radboud University Medical Center Nijmegen, Netherlands, sequentially assigned them seven groups. Eligible healthy, aged 18-55 years, tested negative for...
As severe acute respiratory coronavirus 2 (SARS-CoV-2) variants continue to emerge, it is important characterize immune responses against which can inform on protection efficacies following booster vaccination. In this study, neutralizing breadth and antigen-specific CD8 + T cell were analyzed in both infection-naïve infection-experienced individuals administration of a bivalent Wuhan-Hu-1+BA.4/5 Comirnaty ® mRNA vaccine. Significantly higher titers found after vaccination compared the...
With no approved antiviral therapies, the continuous emergence and re-emergence of tick-borne encephalitis virus (TBEV) yellow fever (YFV) is a rising concern. We performed head-to-head comparisons activity available nucleos(t)ide analogs (nucs) using relevant human cell lines. Eight existing nucs inhibited TBEV and/or YFV with differential between lines viruses. Remdesivir, uprifosbuvir sofosbuvir were most potent drugs against in liver cells, but they had reduced neural whereas galidesivir...
The evolution of SARS-CoV-2 has led to the emergence numerous variants concern (VOCs), marked by changes in viral spike glycoprotein, primary target for neutralising antibody (nAb) responses. Emerging VOCs, particularly omicron sub-lineages, show resistance nAbs induced prior infection or vaccination. precise protein contributing this remain unclear infectious cell culture systems. In present study, a large panel mutant viruses, each with found including JN.1 and its derivatives KP.2 KP.3,...
<title>Abstract</title> The continuous emergence of SARS-CoV-2 variants concern with mutated spike receptor binding domains has rendered many therapeutic mAbs ineffective. To date, there are no clinically authorized antibodies effective against the predominant circulating sub-lineages BQ and XBB. Here, we report isolation broad potent neutralizing HuMabs from a Danish healthcare worker infected early in pandemic. These include novel genetically unique non-RBD-specific HuMab (K501SP6) which...